Objective The overall goal of SmartMarker is the development of a commercial infrastructure that allows to transform heterogeneous patient health information, typically stored in multiple clinical and health IT systems, into standardized, comparable, consistent, and queryable data. The ultimate goal of this infrastructure is to conduct retrospective clinical biomarker validation studies and to foster effective treatments to marker-defined patient subgroups. Exploitation of the electronic medical records will allow pragmatic and low cost, but still robust and appropriate analytical retrospective study methods to measure the prognostic and predictive outcome of clinical biomarkers. SmartMarker will dramatically ease the process of clinical biomarker validation in the cardiology domain. Ischemic heart disease is the leading cause of death in the developed world. The primary biomarker used to identify patients at high risk of sudden death is the ejection fraction. Brain natriuretic peptide is a useful biomarker for predicting the presence of heart failure, risk of readmission and mortality. However, only few biomarkers have been rigorously validated in clinical routine, and few of these markers have been integrated for identifying high risk cohorts in routine clinical practice. This led to a widening implementation gap between recommendations from national and international guidelines and actual routine clinical practice. With SmartMarker we want to close this gap and achieve best-possible outcomes for the patients. We will validate the link between already existing clinical biomarkers in cardiology that are collected on a daily basis in the clinical routine and pertinent clinical endpoints. Finally, we bring forward effective treatments to marker-defined patient subgroups. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencescomputer and information sciencesdata sciencemedical and health scienceshealth scienceshealth care serviceseHealthmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinecardiology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2015 Funding Scheme SME-1 - SME instrument phase 1 Coordinator AVERBIS GMBH Net EU contribution € 50 000,00 Address Salzstrasse 15 79098 Freiburg im breisgau Germany See on map Region Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
